| Year |
Citation |
Score |
| 2023 |
Long M, Wang L, Leach V, Muthusamy N, Byrd JC. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment. Blood Advances. PMID 37871327 DOI: 10.1182/bloodadvances.2023010971 |
0.331 |
|
| 2023 |
Chan WK, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, Sharma A, Hout I, Nishat S, Hanel W, Sloan SL, Yasin A, Denlinger N, Zhang X, Muthusamy N, et al. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Experimental Hematology & Oncology. 12: 79. PMID 37740214 DOI: 10.1186/s40164-023-00437-8 |
0.425 |
|
| 2023 |
Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, et al. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. PMID 37598282 DOI: 10.1038/s41375-023-02006-8 |
0.33 |
|
| 2022 |
Yano M, Byrd JC, Muthusamy N. Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. Cancers. 14. PMID 36497266 DOI: 10.3390/cancers14235787 |
0.331 |
|
| 2022 |
Chiang CL, Hu EY, Chang L, Labanowska J, Zapolnik K, Mo X, Shi J, Doong TJ, Lozanski A, Yan PS, Bundschuh R, Walker LA, Gallego-Perez D, Lu W, Long M, ... ... Muthusamy N, et al. Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity. Cell Reports. 40: 111115. PMID 35858552 DOI: 10.1016/j.celrep.2022.111115 |
0.344 |
|
| 2022 |
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Advances. PMID 35486482 DOI: 10.1182/bloodadvances.2021005883 |
0.417 |
|
| 2022 |
Collard JP, McKenna MK, Noothi SK, Alhakeem SS, Rivas JR, Rangnekar VM, Muthusamy N, Bondada S. Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice. Leukemia & Lymphoma. 1-13. PMID 35258388 DOI: 10.1080/10428194.2022.2045596 |
0.304 |
|
| 2021 |
Hu EY, Do P, Goswami S, Nunes J, Chiang CL, Elgamal S, Ventura AM, Cheney C, Zapolnik K, Williams E, Mani R, Frissora F, Mo X, Waldmeier L, Beerli RR, ... ... Muthusamy N, et al. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Advances. 5: 3152-3162. PMID 34424320 DOI: 10.1182/bloodadvances.2020003276 |
0.379 |
|
| 2021 |
Rivas JR, Liu Y, Alhakeem SS, Eckenrode JM, Marti F, Collard JP, Zhang Y, Shaaban KA, Muthusamy N, Hildebrandt GC, Fleischman RA, Chen L, Thorson JS, Leggas M, Bondada S. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia. Leukemia. PMID 33731852 DOI: 10.1038/s41375-021-01217-1 |
0.31 |
|
| 2020 |
Hu EY, Blachly JS, Saygin C, Ozer HG, Workman SE, Lozanski A, Doong TJ, Chiang CL, Bhat S, Rogers KA, Woyach JA, Coombes KR, Jones D, Muthusamy N, Lozanski G, et al. LC-FACSeq is a method for detecting rare clones in leukemia. Jci Insight. 5. PMID 32554930 DOI: 10.1172/Jci.Insight.134973 |
0.352 |
|
| 2020 |
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy. PMID 32303428 DOI: 10.1016/J.Jcyt.2020.02.001 |
0.469 |
|
| 2020 |
Walker LA, Sovic MG, Chiang CL, Hu E, Denninger JK, Chen X, Kirby ED, Byrd JC, Muthusamy N, Bundschuh R, Yan P. CLEAR: coverage-based limiting-cell experiment analysis for RNA-seq. Journal of Translational Medicine. 18: 63. PMID 32039730 DOI: 10.1186/S12967-020-02247-6 |
0.318 |
|
| 2020 |
Hofmann MH, Mani R, Engelhardt H, Impagnatiello MA, Carotta S, Kerenyi M, Lorenzo-Herrero S, Böttcher J, Scharn D, Arnhof H, Zoephel A, Schnitzer R, Gerstberger T, Sanderson MP, Rajgolikar G, ... ... Muthusamy N, et al. Selective and potent CDK8/19 inhibitors enhance NK cell activity and promote tumor surveillance. Molecular Cancer Therapeutics. PMID 32024684 DOI: 10.1158/1535-7163.Mct-19-0789 |
0.445 |
|
| 2019 |
Chiang CL, Goswami S, Frissora FW, Xie Z, Yan PS, Bundschuh R, Walker LA, Huang X, Mani R, Mo XM, Baskar S, Rader C, Phelps MA, Marcucci G, Byrd JC, ... ... Muthusamy N, et al. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in CLL mouse model. Blood. PMID 31151986 DOI: 10.1182/Blood.2018882290 |
0.418 |
|
| 2019 |
Greene JT, Mani R, Ramaswamy R, Frissora F, Yano M, Zapolnik K, Harrington B, Wasmuth R, Tran M, Mo X, McKenna M, Rangnekar VM, Byrd JC, Bondada S, Muthusamy N. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling. Blood Advances. 3: 1255-1266. PMID 30987970 DOI: 10.1182/Bloodadvances.2018025973 |
0.451 |
|
| 2019 |
Do P, Beckwith KA, Cheney C, Tran M, Beaver L, Griffin BG, Mo X, Liu Y, Lapalombella R, Hertlein E, Muthusamy N, Byrd JC. Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. Journal of Immunology (Baltimore, Md. : 1950). PMID 30910862 DOI: 10.4049/Jimmunol.1801359 |
0.514 |
|
| 2019 |
McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE, Butchar J, Tridandapani S, ... ... Muthusamy N, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Advances. 3: 447-460. PMID 30737226 DOI: 10.1182/Bloodadvances.2018025684 |
0.492 |
|
| 2019 |
Lance JR, Yano M, Mo X, Lee DA, Muthusamy N, Byrd JC. IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL Blood. 134: 4303-4303. DOI: 10.1182/Blood-2019-131034 |
0.469 |
|
| 2019 |
Mohamed Khalil S, Goswami S, Mo X, Muthusamy N. Protein Phosphatase 2A Activation Dependent Down Regulation of PGC1-Alpha and FOXO1 Phosphorylation with OSU-2S in Human Lymphoma Cells Blood. 134: 3977-3977. DOI: 10.1182/Blood-2019-129224 |
0.374 |
|
| 2019 |
Goswami S, Chiang C, Zapolnik K, Xie Z, Lee JL, Baskar S, Rader C, Byrd JC, Phelps MA, Bhatnagar B, Muthusamy N. ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL Blood. 134: 3798-3798. DOI: 10.1182/Blood-2019-128828 |
0.455 |
|
| 2019 |
Yano M, Lance JR, Mo X, Lee DA, Muthusamy N, Byrd JC. IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL Blood. 134: 4302-4302. DOI: 10.1182/Blood-2019-127620 |
0.47 |
|
| 2019 |
Hu E, Ozer HG, Lozanski A, Doong T, Chiang C, Bhat SA, Rogers KA, Woyach J, Blachly JS, Lozanski G, Muthusamy N, Byrd JC. LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia Blood. 134: 3377-3377. DOI: 10.1182/Blood-2019-126070 |
0.386 |
|
| 2019 |
Long M, Williams E, Berard C, Cheney C, Hu E, Bhat SA, Rogers KA, Woyach J, Muthusamy N, Byrd JC. Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity Blood. 134: 1049-1049. DOI: 10.1182/Blood-2019-125417 |
0.427 |
|
| 2019 |
Hofmann MH, Mani R, Engelhardt H, Impagnatiello MA, Carotta S, Kerenyi MA, Lorenzo-Herrero S, Boettcher J, Scharn D, Arnhof H, Zoephel A, Schnitzer R, Gerstberger T, Rajgolikar G, Goswami S, ... ... Muthusamy N, et al. Abstract 510: Selective and potent CDK8 inhibitors enhance NK cell activity and promote tumor surveillance Cancer Research. 79: 510-510. DOI: 10.1158/1538-7445.Am2019-510 |
0.43 |
|
| 2019 |
Yano M, Do P, Mo X, Muthusamy N, Byrd JC. Abstract 3959: Ibrutinib immunomodulation via CTLA4 downregulation in CLL Cancer Research. 79: 3959-3959. DOI: 10.1158/1538-7445.Am2019-3959 |
0.458 |
|
| 2019 |
Hu E, Do P, Mani R, Frissora F, Pearson R, Lozanski G, Peng H, Waldmeier L, Beerli R, Rader C, Grawunder U, Byrd J, Muthusamy N. Abstract 1541: Evaluation of ROR1 targeted antibody drug conjugate in ROR1 positive leukemia Cancer Research. 79: 1541-1541. DOI: 10.1158/1538-7445.Am2019-1541 |
0.523 |
|
| 2019 |
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd J, Lee D, Muthusamy N, Vasu S. Fc engineered anti-CD33mAb potentiates cytotoxicity of mbIL-21 expanded NK-cells against primary AML pre-treated with decitabine Cytotherapy. 21: S20. DOI: 10.1016/J.Jcyt.2019.03.318 |
0.469 |
|
| 2018 |
Dong S, Harrington BK, Hu EY, Greene JT, Lehman AM, Tran M, Wasmuth RL, Long M, Muthusamy N, Brown JR, Johnson AJ, Byrd JC. PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. The Journal of Clinical Investigation. PMID 30457982 DOI: 10.1172/Jci99386 |
0.488 |
|
| 2018 |
Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tranh M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, ... ... Muthusamy N, et al. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34CD123 cells from acute myeloid leukemia / myelodysplastic syndrome patients and healthy donors. Haematologica. PMID 29773600 DOI: 10.3324/Haematol.2018.188193 |
0.451 |
|
| 2018 |
Alhakeem SS, McKenna MK, Oben KZ, Noothi SK, Rivas JR, Hildebrandt GC, Fleischman RA, Rangnekar VM, Muthusamy N, Bondada S. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity. Journal of Immunology (Baltimore, Md. : 1950). PMID 29712773 DOI: 10.4049/Jimmunol.1800241 |
0.396 |
|
| 2018 |
McKenna MK, Noothi SK, Alhakeem SS, Oben KZ, Greene JT, Mani R, Perry KL, Collard JP, Rivas JR, Hildebrandt G, Fleischman R, Durbin EB, Byrd JC, Wang C, Muthusamy N, et al. Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. Blood. PMID 29695515 DOI: 10.1182/Blood-2017-10-813931 |
0.476 |
|
| 2018 |
Gopalakrishnan B, Cheney C, Mani R, Mo X, Bucci D, Walker A, Klisovic R, Bhatnagar B, Walsh K, Rueter B, Waizenegger IC, Heider KH, Blum W, Vasu S, Muthusamy N. Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget. 9: 9706-9713. PMID 29515764 DOI: 10.18632/Oncotarget.23880 |
0.467 |
|
| 2018 |
Stiff A, Trikha P, Mundy-Bosse BL, McMichael EL, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, Landi I, Hsu V, Duggan MC, Wesolowski R, Old M, ... ... Muthusamy N, et al. Nitric Oxide Production by Myeloid Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29363526 DOI: 10.1158/1078-0432.Ccr-17-0691 |
0.414 |
|
| 2018 |
Larkin K, Guth E, Harrington BK, Grieselhuber N, Muthusamy N, Byrd JC. CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy Blood. 132: 4056-4056. DOI: 10.1182/Blood-2018-99-117262 |
0.52 |
|
| 2018 |
Hu E, Waibl-Polania J, Frissora F, Beaver LS, Zapolnik K, Mundy-Bosse BL, Mishra A, Freud AG, Yu J, Byrd JC, Oakes CC, Ostrowski M, Muthusamy N. The ETS1 Transcription Factor Is Implicated in Human and Murine Intermediate NK Cell Development Stages Blood. 132: 2567-2567. DOI: 10.1182/Blood-2018-99-115261 |
0.389 |
|
| 2017 |
Tsai YT, Lakshmanan A, Lehman A, Harrington BK, Lucas FM, Tran M, Sass EJ, Long M, Flechtner AD, Jaynes F, La Perle K, Coppola V, Lozanski G, Muthusamy N, Byrd JC, et al. BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. Blood Advances. 1: 2147-2160. PMID 29296862 DOI: 10.1182/Bloodadvances.2017006593 |
0.522 |
|
| 2017 |
Oben KZ, Alhakeem SS, McKenna MK, Brandon JA, Mani R, Noothi SK, Jinpeng L, Akunuru S, Dhar SK, Singh IP, Liang Y, Wang C, Abdel-Latif A, Stills HF, St Clair DK, ... ... Muthusamy N, et al. Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A. Oncotarget. 8: 77436-77452. PMID 29100399 DOI: 10.18632/Oncotarget.20497 |
0.418 |
|
| 2017 |
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, ... ... Muthusamy N, et al. Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of Clinical Investigation. PMID 28714866 DOI: 10.1172/Jci89756 |
0.367 |
|
| 2017 |
Chiang C, Goswami S, Mani R, Frissora F, Xie Z, Huang X, Baskar S, Rader C, Phelps MA, Marcucci G, Byrd JC, Lee JL, Muthusamy N. Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest Blood. 130: 4981-4981. DOI: 10.1182/Blood.V130.Suppl_1.4981.4981 |
0.408 |
|
| 2017 |
Awan FT, Thangavadivel S, Weiss D, Wei L, Woyach JA, Rogers KA, Jones J, Andritsos L, Muthusamy N, Andersen B, Byrd JC. A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL Blood. 130: 1748-1748. DOI: 10.1182/Blood.V130.Suppl_1.1748.1748 |
0.316 |
|
| 2017 |
Goswami S, Mani R, Mo X, Yan PS, Broe MB, Bundschuh R, Beaver LS, Zapolnik K, Xie Z, Bucci D, Lucas DM, Walker AR, Mims AS, Klisovic RB, Chen C, ... ... Muthusamy N, et al. OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia Blood. 130: 1247-1247. DOI: 10.1182/Blood.V130.Suppl_1.1247.1247 |
0.465 |
|
| 2017 |
Lakshmanan A, Tsai Y, Lehman A, Sass EJ, Tran M, Lucas F, Long M, Harrington BK, Perle KL, Coppola V, Lozanski G, Muthusamy N, Byrd JC, Grever MR, Lucas DM. Abstract 1029: MAPK-mediated immunomodulation in disseminated murine Emu-TCL1 chronic lymphocytic leukemia Cancer Research. 77: 1029-1029. DOI: 10.1158/1538-7445.Am2017-1029 |
0.531 |
|
| 2016 |
McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 5: e1226720. PMID 27853650 DOI: 10.1080/2162402X.2016.1226720 |
0.508 |
|
| 2016 |
Browning RL, Byrd WH, Gupta N, Jones J, Mo X, Hertlein E, Yu L, Muthusamy N, Byrd JC. Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells. Cancer Immunology Research. PMID 27287425 DOI: 10.1158/2326-6066.Cir-15-0291 |
0.421 |
|
| 2016 |
Mani R, Yan R, Mo X, Chen CS, Phelps MA, Klisovic R, Byrd JC, Kisseberth WC, London CA, Muthusamy N. Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. Veterinary and Comparative Oncology. PMID 27136276 DOI: 10.1111/Vco.12221 |
0.448 |
|
| 2016 |
Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, ... ... Muthusamy N, et al. Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts. Blood. PMID 27013443 DOI: 10.1182/Blood-2015-11-680546 |
0.484 |
|
| 2016 |
Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael EL, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, ... ... Muthusamy N, et al. Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment. Cancer Research. PMID 26880800 DOI: 10.1158/0008-5472.Can-15-1490 |
0.458 |
|
| 2016 |
Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, ... ... Muthusamy N, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. PMID 26813675 DOI: 10.1182/Blood-2015-11-679134 |
0.445 |
|
| 2016 |
Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, ... ... Muthusamy N, et al. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 22: 658-68. PMID 26743340 DOI: 10.1016/J.Bbmt.2015.12.015 |
0.468 |
|
| 2016 |
Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas D, Brooks CL, Walker AR, Blum W, Byrd JC, Lozanski G, ... ... Muthusamy N, et al. SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model Blood. 128: 580-580. DOI: 10.1182/Blood.V128.22.580.580 |
0.503 |
|
| 2016 |
Jones JA, Johnson AJ, Awan FT, Zhao Q, Muthusamy N, Maddocks KJ, Andritsos LA, Rogers KA, Woyach JA, Lozanski G, Heerema NA, Brookfield C, Ruppert AS, Byrd JC. A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features Blood. 128: 4388-4388. DOI: 10.1182/Blood.V128.22.4388.4388 |
0.316 |
|
| 2016 |
Woyach JA, Ruppert AS, Awan FT, Jones J, Andritsos LA, Waymer S, Lozanski G, Muthusamy N, Byrd JC. Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones Blood. 128: 4386-4386. DOI: 10.1182/Blood.V128.22.4386.4386 |
0.33 |
|
| 2016 |
Long M, Beckwith KA, Do P, Bethany ML, Gordon G, Lehman AM, Maddocks KJ, Cheney C, Jones J, Andritsos LA, Awan FT, Fraietta JA, June CH, Maus MV, Woyach JA, ... ... Muthusamy N, et al. Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism Blood. 128: 3238-3238. DOI: 10.1182/Blood.V128.22.3238.3238 |
0.502 |
|
| 2016 |
Do P, Beckwith KA, Beaver L, Griffin BG, Mo X, Jones J, Hertlein EK, Muthusamy N, Byrd JC. Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis Blood. 128: 3221-3221. DOI: 10.1182/Blood.V128.22.3221.3221 |
0.529 |
|
| 2016 |
Smith PL, Yan F, Patton JT, Alinari L, Karkhanis V, Ayers L, Muthusamy N, Mishra A, Ahmed E, Sif S, Lapalombella R, Baiocchi RA. PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas Blood. 128: 2936-2936. DOI: 10.1182/Blood.V128.22.2936.2936 |
0.437 |
|
| 2016 |
Goswami S, Mani R, Chiang C, Frissora FW, Mo X, Xie Z, Bucci D, Gordon A, Lucas DM, Blum W, Walker AR, Mims AS, Klisovic RB, Chen C, Lee RJ, ... ... Muthusamy N, et al. CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia Blood. 128: 2748-2748. DOI: 10.1182/Blood.V128.22.2748.2748 |
0.507 |
|
| 2016 |
Tsai Y, Lakshmanan A, Lehman AM, Sass EJ, Tran M, McClanahan F, Long M, Harrington BK, La Perle K, Coppola V, Lozanski G, Muthusamy N, Byrd JC, Grever MR, Lucas DM. BRAFV600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia Blood. 128: 1206-1206. DOI: 10.1182/Blood.V128.22.1206.1206 |
0.541 |
|
| 2016 |
Long M, Beckwith KA, Do P, Gordon A, Lehman A, Maddocks K, Cheney C, Jones J, Andritsos L, Awan F, Woyach J, Amy JJ, Muthusamy N, Byrd J. Abstract B041: Ibrutinib treatment counteracts the immunosuppressive activity of malignant B cells Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B041 |
0.518 |
|
| 2016 |
Stiff AR, Trikha P, Wesolowski R, Kendra K, Uppati S, Abood D, McMichael E, Duggan M, Campbell A, Muthusamy N, Tridandapani S, Caliguiri M, Byrd JC, Carson WE. Abstract 553: Ibrutinib, a BTK inhibitor, impairs the generation and function of myeloid derived suppressor cells Cancer Research. 76: 553-553. DOI: 10.1158/1538-7445.Am2016-553 |
0.442 |
|
| 2016 |
McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia Oncoimmunology. DOI: 10.1080/2162402X.2016.1226720 |
0.412 |
|
| 2016 |
Miller C, Muthusamy N, Breidenbach H, Puski A, Byrd JC, Heerema NA. Metaphase Cytogenetics in Chronic Lymphocytic Leukemia Current Genetic Medicine Reports. 4: 65-73. DOI: 10.1007/S40142-016-0090-5 |
0.338 |
|
| 2015 |
Browning RL, Mo X, Muthusamy N, Byrd JC. CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway. Oncotarget. 6: 15931-9. PMID 26158860 DOI: 10.18632/Oncotarget.3285 |
0.43 |
|
| 2015 |
Alhakeem SS, Sindhava VJ, McKenna MK, Gachuki BW, Byrd JC, Muthusamy N, Bondada S. Role of B cell receptor signaling in IL-10 production by normal and malignant B-1 cells. Annals of the New York Academy of Sciences. PMID 26096907 DOI: 10.1111/Nyas.12802 |
0.454 |
|
| 2015 |
Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. Experimental Hematology. PMID 25937048 DOI: 10.1016/J.Exphem.2015.04.008 |
0.517 |
|
| 2015 |
Li H, Xu S, Quan J, Yung BC, Pang J, Zhou C, Cho YA, Zhang M, Liu S, Muthusamy N, Chan KK, Byrd JC, Lee LJ, Marcucci G, Lee RJ. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia. Molecular Pharmaceutics. 12: 2010-8. PMID 25871632 DOI: 10.1021/Mp5008212 |
0.464 |
|
| 2015 |
Beckwith KA, Byrd JC, Muthusamy N. Tetraspanins as therapeutic targets in hematological malignancy: a concise review. Frontiers in Physiology. 6: 91. PMID 25852576 DOI: 10.3389/Fphys.2015.00091 |
0.456 |
|
| 2015 |
Motiwala T, Kutay H, Zanesi N, Frissora FW, Mo X, Muthusamy N, Jacob ST. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model. Leukemia. 29: 1350-9. PMID 25482129 DOI: 10.1038/Leu.2014.341 |
0.406 |
|
| 2015 |
Chang L, Howdyshell M, Liao WC, Chiang CL, Gallego-Perez D, Yang Z, Lu W, Byrd JC, Muthusamy N, Lee LJ, Sooryakumar R. Magnetic tweezers-based 3D microchannel electroporation for high-throughput gene transfection in living cells. Small (Weinheim An Der Bergstrasse, Germany). 11: 1818-28. PMID 25469659 DOI: 10.1002/Smll.201402564 |
0.396 |
|
| 2015 |
Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, ... ... Muthusamy N, et al. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia. 29: 346-55. PMID 24947019 DOI: 10.1038/leu.2014.199 |
0.732 |
|
| 2015 |
Woyach JA, Ruppert AS, Awan F, Jones JA, Waymer S, Lozanski G, Muthusamy N, Byrd JC. A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) Blood. 126: 2953-2953. DOI: 10.1182/Blood.V126.23.2953.2953 |
0.354 |
|
| 2015 |
Long M, Beckwith KA, Maddocks KJ, Cheney C, Woyach JA, Johnson AJ, Muthusamy N, Byrd JC. Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients Blood. 126: 2940-2940. DOI: 10.1182/Blood.V126.23.2940.2940 |
0.482 |
|
| 2015 |
Chiang C, Frissora FW, Xie Z, Huang X, Mani R, Baskar S, Rader C, Chan KK, Marcucci G, Byrd JC, Lee LJ, Muthusamy N. Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia Blood. 126: 1743-1743. DOI: 10.1182/Blood.V126.23.1743.1743 |
0.432 |
|
| 2015 |
Nooti S, McKenna M, Gachuki B, Byrd J, Muthusamy N, Rangnekar V, Bondada S. Role of Prostate apoptosis response-4 tumor suppressor in the survival and growth of Chronic Lymphocytic Leukemia Clinical Lymphoma Myeloma and Leukemia. 15: S28. DOI: 10.1182/Blood.V126.23.1731.1731 |
0.523 |
|
| 2015 |
Nooti SK, McKenna MK, Frissora FW, Gachuki BW, Alhakeem SS, Greene JT, Muthusamy N, Rangnekar VM, Bondada S. Role of Prostate Apoptosis Response-4 Tumor Suppressor in the Survival and Growth of Chronic Lymphocytic Leukemia Blood. 126: 1731-1731. DOI: 10.1182/blood.v126.23.1731.1731 |
0.432 |
|
| 2015 |
McWilliams E, Mele JM, Fiazuddin F, Cheney C, Muthusamy N, Awan FT. Targeting the Tumor Evasion Interaction of NKG2A and Its Ligand HLA-E Increases Natural-Killer Cell Activity in Chronic Lymphocytic Leukemia Blood. 126: 1289-1289. DOI: 10.1182/Blood.V126.23.1289.1289 |
0.521 |
|
| 2015 |
Beckwith KA, Williams EI, Wright MD, van Spriel AB, Byrd JC, Muthusamy N. The Role of Tetraspanin CD37 in B-Cell Malignancy Blood. 126: 1258-1258. DOI: 10.1182/Blood.V126.23.1258.1258 |
0.51 |
|
| 2015 |
Mani R, Chiang C, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Phelps M, Chen C, Lee R, Byrd J, Baiocchi R, Lee LJ, Muthusamy N. Abstract 4406: ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphomain-vitroandin-vivo Cancer Research. 75: 4406-4406. DOI: 10.1158/1538-7445.Am2015-4406 |
0.551 |
|
| 2015 |
Mani R, Gopalakrishnan B, Mo X, Brooks C, Blum W, Lozanski G, Vasu S, Muthusamy N. Abstract 1691: SL-401 activity against AML blasts correlates with CD123 levels and does not down-regulate CD123 expression Cancer Research. 75: 1691-1691. DOI: 10.1158/1538-7445.Am2015-1691 |
0.46 |
|
| 2015 |
Bertani P, Lu W, Chang L, James Lee L, Chiang C, Muthusamy N. Bosch etching for the creation of a 3D nanoelectroporation system for high throughput gene delivery Journal of Vacuum Science and Technology B: Nanotechnology and Microelectronics. 33. DOI: 10.1116/1.4932157 |
0.31 |
|
| 2014 |
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. The Journal of Clinical Investigation. 124: 4867-76. PMID 25271622 DOI: 10.1172/Jci75328 |
0.492 |
|
| 2014 |
Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MA. Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 98: 160-5. PMID 24927402 DOI: 10.1016/J.Jpba.2014.05.022 |
0.633 |
|
| 2014 |
Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 123: 1957-60. PMID 24652965 DOI: 10.1182/Blood-2014-01-547869 |
0.487 |
|
| 2014 |
Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. Mabs. 6: 749-55. PMID 24594909 DOI: 10.4161/Mabs.28282 |
0.445 |
|
| 2014 |
Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia. 28: 1365-8. PMID 24451411 DOI: 10.1038/Leu.2014.42 |
0.33 |
|
| 2014 |
Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 28: 1501-10. PMID 24445867 DOI: 10.1038/Leu.2014.32 |
0.519 |
|
| 2014 |
Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ, Muthusamy N. A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery. Nanomedicine : Nanotechnology, Biology, and Medicine. 10: 393-400. PMID 23969101 DOI: 10.1016/J.Nano.2013.08.001 |
0.723 |
|
| 2014 |
Brooks C, Chen J, Lucas DM, Muthusamy N, Bergstein I, Rowinsky E. SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia Blood. 124: 5663-5663. DOI: 10.1182/Blood.V124.21.5663.5663 |
0.494 |
|
| 2014 |
Stephens DM, Beckwith KA, Cheney C, Mo X, Flynn JM, Jones JA, Maddocks KJ, Heider K, Muthusamy N, Byrd JC. BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia Blood. 124: 4681-4681. DOI: 10.1182/Blood.V124.21.4681.4681 |
0.502 |
|
| 2014 |
Vasu S, Bingman A, Geyer S, Elder P, Kitzler R, Bradbury H, Odonnell L, Blum W, Jaglowski SM, Andritsos LA, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, ... Muthusamy N, et al. Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation Blood. 124: 2494-2494. DOI: 10.1182/Blood.V124.21.2494.2494 |
0.472 |
|
| 2014 |
Browning RL, Jones JA, Johnson AJ, Muthusamy N, Byrd JC. Abstract 2578: Synergistic activity of lenalidomide and interleukin-21 in chronic lymphocytic leukemia Cancer Research. 74: 2578-2578. DOI: 10.1158/1538-7445.Am2014-2578 |
0.387 |
|
| 2014 |
Yang CS, Dubovsky JA, Chappell DL, Harrington BK, Jaglowski S, Woyach JA, Johnson AJ, Muthusamy N, Byrd JC. Abstract 2557: Immune modulating agent ibrutinib blocks T-helper 17 activation and release of IL-17A while preserving T-regulatory cell function Cancer Research. 74: 2557-2557. DOI: 10.1158/1538-7445.Am2014-2557 |
0.395 |
|
| 2013 |
Wu Y, Kwak KJ, Agarwal K, Marras A, Wang C, Mao Y, Huang X, Ma J, Yu B, Lee R, Vachani A, Marcucci G, Byrd JC, Muthusamy N, Otterson G, et al. Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. Analytical Chemistry. 85: 11265-74. PMID 24102152 DOI: 10.1021/Ac401983W |
0.653 |
|
| 2013 |
Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood. 122: 3308-16. PMID 24009233 DOI: 10.1182/Blood-2013-05-504597 |
0.407 |
|
| 2013 |
Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani S. Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies. The Journal of Biological Chemistry. 288: 26800-9. PMID 23902770 DOI: 10.1074/Jbc.M113.485185 |
0.339 |
|
| 2013 |
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, ... ... Muthusamy N, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 122: 2539-49. PMID 23886836 DOI: 10.1182/Blood-2013-06-507947 |
0.385 |
|
| 2013 |
Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, ... ... Muthusamy N, et al. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. Mabs. 5: 723-35. PMID 23883821 DOI: 10.4161/Mabs.25282 |
0.543 |
|
| 2013 |
Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials. 34: 6185-93. PMID 23726226 DOI: 10.1016/J.Biomaterials.2013.04.063 |
0.743 |
|
| 2013 |
Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, ... ... Muthusamy N, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2355-67. PMID 23493348 DOI: 10.1158/1078-0432.Ccr-12-3191 |
0.307 |
|
| 2013 |
Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. Journal of Immunology (Baltimore, Md. : 1950). 190: 2702-11. PMID 23418626 DOI: 10.4049/Jimmunol.1202588 |
0.515 |
|
| 2013 |
Baskar S, Muthusamy N. Antibody-based therapeutics for the treatment of human B cell malignancies. Current Allergy and Asthma Reports. 13: 33-43. PMID 23229130 DOI: 10.1007/S11882-012-0327-7 |
0.484 |
|
| 2013 |
Raghunandan R, Frissora FW, Muthusamy N. Modulation of Ets-1 expression in B lymphocytes is dependent on the antigen receptor-mediated activation signals and cell cycle status. Scandinavian Journal of Immunology. 77: 75-83. PMID 23216019 DOI: 10.1111/Sji.12012 |
0.41 |
|
| 2013 |
Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, Phelps M, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, Byrd JC, Muthusamy N. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 347-56. PMID 23209030 DOI: 10.1158/1078-0432.Ccr-12-2046 |
0.749 |
|
| 2013 |
Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, ... Muthusamy N, et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood. 121: 136-47. PMID 23165478 DOI: 10.1182/Blood-2012-01-407742 |
0.724 |
|
| 2013 |
McWilliams EM, Cheney C, Jones JA, Flynn JMM, Maddocks K, Andritsos LA, Huet H, Gram H, Baeck J, Muthusamy N, Byrd JC. B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo Blood. 122: 4185-4185. DOI: 10.1182/Blood.V122.21.4185.4185 |
0.525 |
|
| 2013 |
Mani R, Mao Y, Frissora FW, Chiang C, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Lee RJ, Chen C, ... ... Muthusamy N, et al. Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia Blood. 122: 4168-4168. DOI: 10.1182/Blood.V122.21.4168.4168 |
0.75 |
|
| 2013 |
He S, Cheney C, Whitman SP, Yu J, Vasu S, Blum W, Heider K, Marcucci G, Muthusamy N. Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy Blood. 122: 3959-3959. DOI: 10.1182/Blood.V122.21.3959.3959 |
0.529 |
|
| 2013 |
Wang H, Santhanam R, Xie Z, Huang X, Chiu M, Phelps MA, Walker AR, Caligiuri MA, Garzon R, Lee J, Muthusamy N, Chan KK, Marcucci G. A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b Blood. 122: 3933-3933. DOI: 10.1182/Blood.V122.21.3933.3933 |
0.345 |
|
| 2013 |
Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC. Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity Blood. 122: 373-373. DOI: 10.1182/Blood.V122.21.373.373 |
0.482 |
|
| 2013 |
Chappell DL, Dubovsky JA, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Agrawal K, Byrd JC, Muthusamy N. Abstract 4925: Lymphocyte cytosolic protein 1 (LCP1) is a membrane-associated molecular target in chronic lymphocytic leukemia and is activated in microenvironment signaling. Cancer Research. 73: 4925-4925. DOI: 10.1158/1538-7445.Am2013-4925 |
0.333 |
|
| 2013 |
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Hessler J, Liu T, Chang BY, Larkin KM, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, ... ... Muthusamy N, et al. Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression. Cancer Research. 73: 492-492. DOI: 10.1158/1538-7445.Am2013-492 |
0.443 |
|
| 2012 |
Timmerman JM, Byrd JC, Andorsky DJ, Yamada RE, Kramer J, Muthusamy N, Hunder N, Pagel JM. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5752-60. PMID 22893631 DOI: 10.1158/1078-0432.Ccr-12-0456 |
0.416 |
|
| 2012 |
Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, ... ... Muthusamy N, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 21: 694-708. PMID 22624718 DOI: 10.1016/J.Ccr.2012.03.040 |
0.396 |
|
| 2012 |
Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC. XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia. 26: 1720-2. PMID 22333878 DOI: 10.1038/Leu.2012.40 |
0.422 |
|
| 2012 |
Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood. 119: 3767-78. PMID 22271448 DOI: 10.1182/Blood-2011-09-381988 |
0.516 |
|
| 2012 |
Fisher IB, Ostrowski M, Muthusamy N. Role for Ets-2(Thr-72) transcription factor in stage-specific thymocyte development and survival. The Journal of Biological Chemistry. 287: 5199-210. PMID 22128184 DOI: 10.1074/Jbc.M111.242602 |
0.319 |
|
| 2012 |
Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, ... ... Muthusamy N, et al. Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells Blood. 120: 775-775. DOI: 10.1182/Blood.V120.21.775.775 |
0.474 |
|
| 2012 |
Butchar JP, Shah P, Patel H, Fatehchand K, Rafiq S, Cheney C, Vasilakos JP, Muthusamy N, Byrd JC, Tridandapani S. TLR7/8 Agonists Overcome the Suppression of FcγR Activity in Monocytes From Chronic Lymphocytic Leukemia Patients Blood. 120: 4595-4595. DOI: 10.1182/Blood.V120.21.4595.4595 |
0.362 |
|
| 2012 |
Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, et al. Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD) Blood. 120: 4192-4192. DOI: 10.1182/Blood.V120.21.4192.4192 |
0.483 |
|
| 2012 |
Chappell DL, Dubovsky JA, Andritsos LA, Flynn JM, Jones JA, Byrd JC, Muthusamy N. Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling Blood. 120: 3866-3866. DOI: 10.1182/Blood.V120.21.3866.3866 |
0.462 |
|
| 2012 |
Huang X, Schwind S, Eisfeld A, Yu B, Santhanam R, Hoellerbauer P, Jin Y, Hickey C, Pang J, Chan KK, Perrotti D, Muthusamy N, Byrd JC, Blum W, Bloomfield CD, et al. Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML). Blood. 120: 2422-2422. DOI: 10.1182/Blood.V120.21.2422.2422 |
0.304 |
|
| 2012 |
Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, et al. Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease Blood. 120: 1949-1949. DOI: 10.1182/Blood.V120.21.1949.1949 |
0.46 |
|
| 2012 |
Beckwith KA, Frissora FW, Stefanovski MR, Deckert J, Croce CM, Mo X, Jarjoura D, Byrd JC, Muthusamy N. A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics Blood. 120: 188-188. DOI: 10.1182/Blood.V120.21.188.188 |
0.542 |
|
| 2012 |
Dubovsky JA, Andritsos LA, Blum W, Johnson A, Muthusamy N, Byrd JC. Abstract 509: Immunoglobulin reactivity analysis of chronic lymphocytic leukemia patients unveils Lymphocyte Cytosolic Protein 1 (LCP1) as a novel CLL exosome antigen Cancer Research. 72: 509-509. DOI: 10.1158/1538-7445.Am2012-509 |
0.434 |
|
| 2012 |
Motiwala T, Zanesi N, Roy S, Mustafa M, Kutay H, You J, Frissora F, Lu Y, Muthusamy N, Freitas M, Croce CM, Jacob ST. Abstract 1351: Analysis of the in vivo tumor suppressive potential of PTPROt (truncated protein tyrosine phosphatase receptor-type O) in CLL using a transgenic mouse model Cancer Research. 72: 1351-1351. DOI: 10.1158/1538-7445.Am2012-1351 |
0.434 |
|
| 2012 |
Huang X, Sebastian S, Eisfeld A, Jin Y, Yu B, Hickey C, Pang J, Ramasamy S, Chan K, Perrotti D, Muthusamy N, Byrd J, Blum W, Bloomfield C, Liu S, et al. Abstract 1111: SyntheticmicroRNA (miR)-181ananoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in acute myeloid leukemia (AML) Cancer Research. 72: 1111-1111. DOI: 10.1158/1538-7445.Am2012-1111 |
0.321 |
|
| 2011 |
Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, ... Muthusamy N, et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 118: 6893-903. PMID 22042694 DOI: 10.1182/Blood-2011-06-363879 |
0.757 |
|
| 2011 |
Muthusamy N, Chen HC, Rajgolikar G, Butz KG, Frissora FW, Gronostajski RM. Recombination activation gene-2-deficient blastocyst complementation analysis reveals an essential role for nuclear factor I-A transcription factor in T-cell activation. International Immunology. 23: 385-90. PMID 21602176 DOI: 10.1093/Intimm/Dxr025 |
0.446 |
|
| 2011 |
Bai LY, Ma Y, Kulp SK, Wang SH, Chiu CF, Frissora F, Mani R, Mo X, Jarjoura D, Byrd JC, Chen CS, Muthusamy N. OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway. British Journal of Haematology. 153: 623-33. PMID 21470196 DOI: 10.1111/J.1365-2141.2010.08443.X |
0.472 |
|
| 2011 |
Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK, Chen CS. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology (Baltimore, Md.). 53: 1943-58. PMID 21391227 DOI: 10.1002/Hep.24293 |
0.343 |
|
| 2011 |
Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 117: 4323-7. PMID 21378270 DOI: 10.1182/Blood-2010-11-315705 |
0.445 |
|
| 2011 |
Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 117: 4530-41. PMID 21228331 DOI: 10.1182/Blood-2010-08-303354 |
0.547 |
|
| 2011 |
Huang X, Schwind S, Yu B, Pang J, Santhanam R, Chan KK, Garzon R, Blum W, Bloomfield CD, Liu S, Perrotti D, Lee RJ, Byrd JC, Muthusamy N, Lee LJ, et al. Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML) Blood. 118: 81-81. DOI: 10.1182/Blood.V118.21.81.81 |
0.347 |
|
| 2011 |
Lapalombella R, Ramanunni A, Yeh Y, Wang L, Jha S, Staubli J, Herman SEM, Andritsos LA, Jones JA, Flynn JM, Mo X, Johnson AJ, Thompson P, Algate PA, Stromatt S, ... ... Muthusamy N, et al. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals Blood. 118: 622-622. DOI: 10.1182/BLOOD.V118.21.622.622 |
0.415 |
|
| 2011 |
Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang C. Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL) Blood. 118: 599-599. DOI: 10.1182/Blood.V118.21.599.599 |
0.488 |
|
| 2011 |
Rafiq S, Butchar JP, Cheney C, Mo X, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JC. Comparative Assessment of Different Clinically Utilized CD20 Directed Antibodies in Chronic Lymphocytic Leukemia (CLL) Cells Reveals Divergent NK-Cell, Monocyte and Macrophage Properties, Blood. 118: 3717-3717. DOI: 10.1182/Blood.V118.21.3717.3717 |
0.453 |
|
| 2011 |
Mani R, Frissora FW, Chen C, Byrd JC, Muthusamy N. OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase Blood. 118: 2499-2499. DOI: 10.1182/Blood.V118.21.2499.2499 |
0.514 |
|
| 2011 |
Muthusamy N, Yu B, Mao Y, Bai L, Herman SE, Ramanunni A, Mo X, Jin Y, Carolyn C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ. 3.23 Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Oligonucleotides and Improves Therapeutic Efficacy Clinical Lymphoma Myeloma and Leukemia. 11: S213. DOI: 10.1016/J.Clml.2011.09.112 |
0.639 |
|
| 2010 |
Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 116: 3705-14. PMID 20610811 DOI: 10.1182/Blood-2010-04-001230 |
0.414 |
|
| 2010 |
Hertlein E, Triantafillou G, Sass EJ, Hessler JD, Zhang X, Jarjoura D, Lucas DM, Muthusamy N, Goldenberg DM, Lee RJ, Byrd JC. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood. 116: 2554-8. PMID 20574049 DOI: 10.1182/Blood-2009-11-253203 |
0.529 |
|
| 2010 |
Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3182-92. PMID 20460491 DOI: 10.1158/1078-0432.Ccr-09-2484 |
0.416 |
|
| 2010 |
Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, ... Muthusamy N, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood. 116: 1025-34. PMID 20427703 DOI: 10.1182/Blood-2009-12-257485 |
0.443 |
|
| 2010 |
Biswas S, Zhao X, Mone AP, Mo X, Vargo M, Jarjoura D, Byrd JC, Muthusamy N. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leukemia Research. 34: 925-31. PMID 20171736 DOI: 10.1016/J.Leukres.2010.01.020 |
0.382 |
|
| 2010 |
Gowda A, Ramanunni A, Cheney C, Rozewski D, Kindsvogel W, Lehman A, Jarjoura D, Caligiuri M, Byrd JC, Muthusamy N. Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia. Mabs. 2: 35-41. PMID 20081380 DOI: 10.4161/Mabs.2.1.10561 |
0.45 |
|
| 2010 |
Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, ... ... Muthusamy N, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 115: 1204-13. PMID 19965644 DOI: 10.1182/Blood-2009-06-229039 |
0.517 |
|
| 2010 |
Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, ... ... Muthusamy N, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 115: 2619-29. PMID 19965642 DOI: 10.1182/Blood-2009-09-242438 |
0.521 |
|
| 2010 |
Jin Y, Liu S, Yu B, Golan S, Koh CG, Yang J, Huynh L, Yang X, Pang J, Muthusamy N, Chan KK, Byrd JC, Talmon Y, Lee LJ, Lee RJ, et al. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia. Molecular Pharmaceutics. 7: 196-206. PMID 19852511 DOI: 10.1021/Mp900205R |
0.396 |
|
| 2010 |
Rafiq S, Cheney CM, Lozanski G, Lapalombella R, Mo X, Siadak A, Jarjoura D, Byrd JC, Muthusamy N. GlycoVariant Anti-CD37 Small Modular Immuno-Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density Blood. 116: 1847-1847. DOI: 10.1182/Blood.V116.21.1847.1847 |
0.556 |
|
| 2010 |
Herman SE, Lapalombella R, Jones JA, Andritsos L, Gordon AL, Ramanunni A, Lannutti B, Muthusamy N, Byrd JC, Johnson AJ. Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia Blood. 116: 1821-1821. DOI: 10.1182/Blood.V116.21.1821.1821 |
0.548 |
|
| 2010 |
Yu B, Mao Y, Bai L, Herman SE, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee R, Lee L, Byrd JC, Muthusamy N. Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia. Blood. 116: 1475-1475. DOI: 10.1182/Blood.V116.21.1475.1475 |
0.721 |
|
| 2009 |
Byrd JC, Lapalombella R, Ramanunni A, Andritsos LA, Flynn JM, Baum P, Thompson P, Muthusamy N. Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3035. PMID 27962079 DOI: 10.1200/Jco.2009.27.15_Suppl.3035 |
0.497 |
|
| 2009 |
Baum PR, Cerveny C, Gordon B, Nilsson C, Wiens J, Rafiq S, Lapalombella R, Muthusamy N, Byrd JC, Wahl A. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8571. PMID 27961015 DOI: 10.1200/Jco.2009.27.15_Suppl.8571 |
0.503 |
|
| 2009 |
Wei G, Srinivasan R, Cantemir-Stone CZ, Sharma SM, Santhanam R, Weinstein M, Muthusamy N, Man AK, Oshima RG, Leone G, Ostrowski MC. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood. 114: 1123-30. PMID 19411629 DOI: 10.1182/Blood-2009-03-211391 |
0.34 |
|
| 2009 |
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 113: 6411-8. PMID 19211935 DOI: 10.1182/Blood-2008-07-170589 |
0.328 |
|
| 2009 |
Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. British Journal of Haematology. 144: 848-55. PMID 19183192 DOI: 10.1111/J.1365-2141.2008.07548.X |
0.537 |
|
| 2009 |
Yang X, Koh CG, Liu S, Pan X, Santhanam R, Yu B, Peng Y, Pang J, Golan S, Talmon Y, Jin Y, Muthusamy N, Byrd JC, Chan KK, Lee LJ, et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Molecular Pharmaceutics. 6: 221-30. PMID 19183107 DOI: 10.1021/Mp800149S |
0.38 |
|
| 2009 |
Joshi T, Ganesan LP, Cheney C, Ostrowski MC, Muthusamy N, Byrd JC, Tridandapani S. The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma. Plos One. 4: e4208. PMID 19148288 DOI: 10.1371/Journal.Pone.0004208 |
0.357 |
|
| 2009 |
Hertlein EK, Triantafillou G, Hessler J, Zhang X, Jarjoura D, Lucas DM, Lee RJ, Muthusamy N, Goldenberg DM, Byrd JC. Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells. Blood. 114: 721-721. DOI: 10.1182/Blood.V114.22.721.721 |
0.525 |
|
| 2009 |
Bai L, Ma Y, Kulp SK, Wang S, Chiu C, Frissora F, Mo X, Jarjoura D, Byrd JC, Chen C, Muthusamy N. OSU-DY7, a Novel D-Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway. Blood. 114: 3778-3778. DOI: 10.1182/Blood.V114.22.3778.3778 |
0.494 |
|
| 2009 |
Alinari L, Liu Q, Chen C, Yan F, Dalton JT, Lapalombella R, Zhang X, Lin T, Byrd JC, Baiocchi RA, Muthusamy N. FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma. Blood. 114: 3728-3728. DOI: 10.1182/Blood.V114.22.3728.3728 |
0.462 |
|
| 2009 |
Awan F, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson D, Cheney C, Mo X, Lehman A, Jones JA, Flynn JM, Jarjoura D, Baiocchi RA, Desjarlais J, Tridandapani S, ... ... Muthusamy N, et al. CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody. Blood. 114: 3725-3725. DOI: 10.1182/Blood.V114.22.3725.3725 |
0.528 |
|
| 2009 |
Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kanneganti T, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson WE, Byrd JC, Tridandapani S. TLR7/8 Differentially Regulates Fcγ Receptor Expression and Function. Blood. 114: 3594-3594. DOI: 10.1182/Blood.V114.22.3594.3594 |
0.333 |
|
| 2009 |
Maddocks K, Lapalombella R, Blum KA, Blum W, Fischer BB, Muthusamy N, Moran ME, Holtzapfel D, Byrd JC, Johnson AJ, Andritsos L. Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia. Blood. 114: 3446-3446. DOI: 10.1182/Blood.V114.22.3446.3446 |
0.325 |
|
| 2009 |
Andritsos L, Furman RR, Flinn IW, Foreno-Torres A, Flynn JM, Muthusamy N, Rafiq S, Stromatt S, Byrd JC. A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity. Blood. 114: 3424-3424. DOI: 10.1182/Blood.V114.22.3424.3424 |
0.385 |
|
| 2009 |
Browning RL, Wang S, Ramanunni A, Muthusamy N, Byrd JC. Transcriptional up-Regulation of IL-21 Receptor-α On CLL Cells by CpG685 through An NF-κB Mediated Pathway Provides a Rationale for Combination Strategies with IL-21. Blood. 114: 2761-2761. DOI: 10.1182/Blood.V114.22.2761.2761 |
0.394 |
|
| 2009 |
Rafiq S, Cheney C, Thompson PA, Siadak T, Algate P, Cerveny C, Byrd JC, Muthusamy N. Glycovariant CD37 Small Modular Immuno-Pharmaceutical (TruADhanCe™ SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells. Blood. 114: 1744-1744. DOI: 10.1182/Blood.V114.22.1744.1744 |
0.564 |
|
| 2009 |
Alinari L, Christian B, Yu B, Shin J, Hertlein EK, Lapalombella R, Yan F, Lesinski G, Zhang X, Lozanski G, Muthusamy N, Goldenberg DM, Byrd JC, Baiocchi RA. Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb. Blood. 114: 1694-1694. DOI: 10.1182/Blood.V114.22.1694.1694 |
0.554 |
|
| 2008 |
Nagaleekar VK, Diehl SA, Juncadella I, Charland C, Muthusamy N, Eaton S, Haynes L, Garrett-Sinha LA, Anguita J, Rincón M. IP3 receptor-mediated Ca2+ release in naive CD4 T cells dictates their cytokine program. Journal of Immunology (Baltimore, Md. : 1950). 181: 8315-22. PMID 19050248 DOI: 10.4049/Jimmunol.181.12.8315 |
0.403 |
|
| 2008 |
Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, ... ... Muthusamy N, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 112: 5180-9. PMID 18772452 DOI: 10.1182/Blood-2008-01-133108 |
0.503 |
|
| 2008 |
Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Research. 68: 1204-12. PMID 18281497 DOI: 10.1158/0008-5472.Can-07-2621 |
0.376 |
|
| 2008 |
Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, et al. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 569-78. PMID 18223233 DOI: 10.1158/1078-0432.Ccr-07-1006 |
0.473 |
|
| 2008 |
Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 111: 4723-30. PMID 18182577 DOI: 10.1182/Blood-2007-07-099531 |
0.39 |
|
| 2008 |
Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 111: 275-84. PMID 17761520 DOI: 10.1182/Blood-2006-10-053884 |
0.493 |
|
| 2008 |
Zhao X, Wu J, Muthusamy N, Byrd JC, Lee RJ. Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment. Journal of Pharmaceutical Sciences. 97: 1508-18. PMID 17722102 DOI: 10.1002/Jps.21046 |
0.427 |
|
| 2007 |
Allen CE, Richards J, Muthusamy N, Auer H, Liu Y, Robinson ML, Barnard JA, Wu LC. Disruption of ZAS3 in mice alters NF-kappaB and AP-1 DNA binding and T-cell development. Gene Expression. 14: 83-100. PMID 18257392 DOI: 10.3727/105221607783417574 |
0.44 |
|
| 2007 |
Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, Caligiuri MA, Leone G. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 104: 15400-5. PMID 17881568 DOI: 10.1073/Pnas.0706307104 |
0.37 |
|
| 2007 |
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/Jci31095 |
0.456 |
|
| 2007 |
Zhao XB, Muthusamy N, Byrd JC, Lee RJ. Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. Journal of Pharmaceutical Sciences. 96: 2424-35. PMID 17588260 DOI: 10.1002/Jps.20885 |
0.315 |
|
| 2007 |
Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 110: 2569-77. PMID 17440052 DOI: 10.1182/Blood-2006-12-062927 |
0.545 |
|
| 2007 |
Gowda AC, Ramanunni A, Cheney C, Roda J, Kindsvogel W, Henderson D, pallavur S, Carson W, Muthusamy N, Byrd JC. IL-21 enhances chemoimmunotherapy mediated death of chronic lymphocytic leukemia cells Journal of Clinical Oncology. 25: 7094-7094. DOI: 10.1200/Jco.2007.25.18_Suppl.7094 |
0.407 |
|
| 2007 |
Lapalombella R, Zhao XB, Baum PR, Ledbetter JA, Muthusamy N, Byrd JC. Role of CD37SMIP a Novel Engineered Small Modular Immunopharmaceutical in the Treatment of CLL. Blood. 110: 801-801. DOI: 10.1182/Blood.V110.11.801.801 |
0.532 |
|
| 2007 |
Garzon R, Liu S, Fabbri M, Liu Z, Pang J, Muthusamy N, Blum W, Chan K, Byrd JC, Croce CM, Marcucci G. MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML). Blood. 110: 718-718. DOI: 10.1182/Blood.V110.11.718.718 |
0.356 |
|
| 2007 |
Roda JM, Gowda A, Hussain R, Ramanunni A, Lehman A, Kindsvogel W, Carson WE, Muthusamy N, Byrd JC. IL-21 Promotes Apoptosis through Induction of the BH3 Only Protein Bim and Enhacnes Direct and Innate Immune-Promoted Death of Chronic Lymphocytic Leukemia Cells. Blood. 110: 3118-3118. DOI: 10.1182/Blood.V110.11.3118.3118 |
0.423 |
|
| 2007 |
Roda JM, Lapalombella R, Baiocchi R, Zhukocsky E, Desjarlais J, Muthusamy N, Byrd JC. Pre-Clinical Activity of a Novel FcγRIIIa Engineered CD19 Monoclonal Antibody in B Cell Chronic Lymphocytic Leukemia and Acute Lymphoblastic Leukemia. Blood. 110: 2351-2351. DOI: 10.1182/Blood.V110.11.2351.2351 |
0.566 |
|
| 2007 |
Joshi T, Ganesan LP, Cheney C, Muthusamy N, Byrd JC, Ostrowski MC, Tridandapani S. A critical role for Akt in macrophage cytotoxicity to antibody‐coated tumor cells The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A184-A |
0.34 |
|
| 2006 |
Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, Croce CM, Grever MR, Byrd JC. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 108: 1334-8. PMID 16670263 DOI: 10.1182/Blood-2005-12-011213 |
0.426 |
|
| 2006 |
Chen HC, Byrd JC, Muthusamy N. Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival. Journal of Immunology (Baltimore, Md. : 1950). 176: 2208-18. PMID 16455977 DOI: 10.4049/Jimmunol.176.4.2208 |
0.423 |
|
| 2006 |
Lapalombella R, Zhao XB, Grosmaire L, Ledbetter JA, Muthusamy N, Byrd JC. CD37−SMIPTM Drug Induced Caspase Independent Cellular Cytotoxicity Is Associated with Activation of Phosphotyrosine-Mediated Signaling Events in Primary Chronic Lymphocytic Leukemia (CLL) B Cells. Blood. 108: 753-753. DOI: 10.1182/Blood.V108.11.753.753 |
0.503 |
|
| 2006 |
Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy D, Caligiuri MA, Bloomfield CD, Chen C, et al. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. Blood. 108: 288-288. DOI: 10.1182/Blood.V108.11.288.288 |
0.465 |
|
| 2006 |
Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Perrotti D, Chen C, Dalton JT, Byrd JC, Muthusamy N. FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma. Blood. 108: 2095-2095. DOI: 10.1182/Blood.V108.11.2095.2095 |
0.506 |
|
| 2006 |
Zhao XB, Trupti J, Lapalombella R, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL. Blood. 108: 135-135. DOI: 10.1182/Blood.V108.11.135.135 |
0.525 |
|
| 2005 |
Johnson AJ, Edwards R, Smith LL, Lucas DM, Croce CM, Muthusamy N, Chen C, Liu Z, Chan K, Grever MR, Byrd JC. The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia. Blood. 106: 51-51. DOI: 10.1182/Blood.V106.11.51.51 |
0.453 |
|
| 2005 |
Gowda AC, Zhao XB, Cheney C, Mehter N, Lozanski G, Lin TS, Guster S, Drachman JG, Muthusamy N, Byrd JC. Humanized Anti CD-40 Antibody SGN-40 Effectively Induces Cytotoxicity Against Chronic Lymphocytic Leukemia (CLL) Cells through Antibody Mediated Cytotoxicity and Demonstrates Modest Biologic Evidence of CD40 Activation. Blood. 106: 2966-2966. DOI: 10.1182/Blood.V106.11.2966.2966 |
0.533 |
|
| 2004 |
Biswas S, Mone AP, Sen CK, Muthusamy N, Byrd JC. Arsenic Trioxide and Ascorbic Acid Enhances the Cytotoxicity of Hu1D10 towards CLL Cells. Blood. 104: 3479-3479. DOI: 10.1182/Blood.V104.11.3479.3479 |
0.429 |
|
| 2004 |
Muthusamy N, Chen H, Frissora F, Byrd JC. Generation and Analysis of Transgenic Mice Reveal a Role for CRE Binding Proteins in Multiple Stages of B Cell Development, Functional Maturation, Proliferation and Apoptosis. Blood. 104: 3233-3233. DOI: 10.1182/Blood.V104.11.3233.3233 |
0.439 |
|
| 2004 |
Zhao XB, Biswas S, Mone A, Ledbetter J, Ledbetter MH, Grosmaire L, Espling E, Cheney C, Young D, Lee RJ, Muthusamy N, Byrd JC. Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells. Blood. 104: 2515-2515. DOI: 10.1182/Blood.V104.11.2515.2515 |
0.506 |
|
| 2003 |
Muthusamy N, Park DJ, Rho HW, Rhee SG, Subbarao B. Impaired antigen receptor induced calcium mobilization in a phospholipase C-gamma1 deficient B cell line. Immunology Letters. 90: 203-7. PMID 14687726 DOI: 10.1016/J.Imlet.2003.09.010 |
0.415 |
|
| 2003 |
Chen HC, Frissora F, Durbin JE, Muthusamy N. Activation induced differential regulation of stem cell antigen-1 (Ly-6A/E) expression in murine B cells. Cellular Immunology. 225: 42-52. PMID 14643303 DOI: 10.1016/J.Cellimm.2003.09.006 |
0.362 |
|
| 2003 |
Frissora F, Chen HC, Durbin J, Bondada S, Muthusamy N. IFN-gamma-mediated inhibition of antigen receptor-induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor. European Journal of Immunology. 33: 907-12. PMID 12672056 DOI: 10.1002/Eji.200323657 |
0.396 |
|
| 2002 |
Allen CE, Muthusamy N, Weisbrode SE, Hong JW, Wu LC. Developmental anomalies and neoplasia in animals and cells deficient in the large zinc finger protein KRC. Genes, Chromosomes & Cancer. 35: 287-98. PMID 12378523 DOI: 10.1002/Gcc.10128 |
0.448 |
|
| 2002 |
Ding W, Albrecht B, Kelley RE, Muthusamy N, Kim SJ, Altschuld RA, Lairmore MD. Human T-cell lymphotropic virus type 1 p12(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T cells. Journal of Virology. 76: 10374-82. PMID 12239314 DOI: 10.1128/Jvi.76.20.10374-10382.2002 |
0.312 |
|
| 1993 |
Muthusamy N, Bondada S. Differential regulation of surface immunoglobulin and Lyb2 mediated B cell activation: II. cAMP dependent (prostaglandin E2) and independent (IFN-gamma) mechanisms of regulation of B lymphocyte activation. International Immunology. 5: 949-56. PMID 8398988 DOI: 10.1093/Intimm/5.8.949 |
0.305 |
|
| 1989 |
Nagarkatti PS, Seth A, Nagarkatti M, Muthusamy N, Rychlik B, Subbarao B. A specific defect in the proliferative capacity of B cells from old mice stimulated with autoreactive T cells. Cellular Immunology. 120: 102-13. PMID 2784718 DOI: 10.1016/0008-8749(89)90178-0 |
0.316 |
|
| Show low-probability matches. |